Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy

BACKGROUND: Patients with COVID-19 receiving ritonavir-containing therapies are at risk of potential drug-drug interactions (pDDIs) because of ritonavir’s effects on cytochrome P450 3A4. OBJECTIVE: To assess the prevalence of pDDIs with ritonavir-containing COVID-19 therapy in adults with COVID-19 u...

Descripción completa

Detalles Bibliográficos
Autores principales: Igho-Osagie, Ebuwa, Puenpatom, Amy, Williams, Marissa Grifasi, Song, Yan, Yi, Denise, Wang, Jessie, Berman, Richard, Gu, Miley, He, Chujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394216/
https://www.ncbi.nlm.nih.gov/pubmed/36989455
http://dx.doi.org/10.18553/jmcp.2023.22366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394216/
https://www.ncbi.nlm.nih.gov/pubmed/36989455
http://dx.doi.org/10.18553/jmcp.2023.22366

Ejemplares similares